Visterra Announces Additions to its Management Team and Board of Directors

Visterra Announces Additions to its Management Team and Board of Directors

October 31, 2014

– Veteran Biotech Executive José M. Trevejo, MD, PhD, to Head Clinical Development and Regulatory Affairs; Industry Leader Akshay Vaishnaw, MD, PhD, FRCP Elected to Board –

Novomer Announces First Commercial Adoption of Converge® Polyols for Polyurethane Adhesives

Novomer Announces First Commercial Adoption of Converge® Polyols for Polyurethane Adhesives

October 27, 2014

WALTHAM, Mass., October 27, 2014 - Novomer Inc., a sustainable materials company pioneering a family of high-performance polymers and other chemicals from renewable feedstocks such as carbon dioxide (CO2), has announced that Jowat AG, a leading supplier of industrial adhesives headquartered in Germany, is the first to commercially adopt Novomer’s new Converge® polypropylene carbonate (PPC) polyols for use in polyurethane hot melt adhesive applications.

Nielsen Acquires Affinnova

Nielsen Acquires Affinnova

October 30, 2014

New York – Oct. 30, 2014 – Nielsen, a leading global provider of information and insights into what consumers watch and buy, has recently completed its acquisition of Affinnova, an international media and marketing research firm. The Affinnova team will become part of Nielsen’s Innovation Practice area, expanding the team globally and accelerating delivery of a suite of digitally-enabled, innovative solutions for every step of the new product development and activation process.

Syros Pharmaceuticals Closes $53 Million Series B Financing

Syros Pharmaceuticals Closes $53 Million Series B Financing

October 27, 2014

 - Includes Leading Public and Healthcare-Focused Funds -

- Proceeds Will Accelerate Gene Control Programs and Platform -

The TransMedics® Organ Care System (OCS™) Heart Technology Was Used to Perform The World’s First Series of Adult Human Heart Transplants From Donors After Circulatory Death (DCD Donors) at St Vincent’s Hospital in Sydney, Australia

The TransMedics® Organ Care System (OCS™) Heart Technology Was Used to Perform The World’s First Series of Adult Human Heart Transplants From Donors After Circulatory Death (DCD Donors) at St Vincent’s Hospital in Sydney, Australia

October 24, 2014

Andover, Mass. - October 24, 2014  - TransMedics announces that its OCS™ Heart technology was used successfully to preserve and assess the world’s first series of three successful adult heart transplant procedures from hearts donated from donors after circulatory death (DCD) by the St. Vincent’s Hospital Heart Transplant team. All patients who received these groundbreaking transplants have recovered very well.

Eleven Biotherapeutics Appoints Wendy L. Dixon, PhD to Board of Directors

Eleven Biotherapeutics Appoints Wendy L. Dixon, PhD to Board of Directors

October 23, 2014

 - Senior Biopharmaceutical Executive with Commercial Leadership Experience from Bristol Myers Squibb and Merck and Co.-

Agios Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with an IDH2 Mutation

Agios Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with an IDH2 Mutation

October 21, 2014

AG-221 Now Being Evaluated in Broad Range of Cancers

Moderna to Collaborate with Karolinska Institutet and Karolinska University Hospital on Discovery of New Messenger RNA Therapeutics™

Moderna to Collaborate with Karolinska Institutet and Karolinska University Hospital on Discovery of New Messenger RNA Therapeutics™

October 16, 2014

Strategic research and clinical partnership will advance state-of-the-art discoveries on the use of messenger RNA (mRNA) Therapeutics™ to treat serious diseases
Company to establish Moderna Therapeutics Sweden in Stockholm as first expansion outside the U.S.

Agios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221

Agios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221

October 15, 2014

 Once-Daily Oral Dose Selected From Ongoing Phase 1 Study of AG-221 in Hematologic Malignancies

Data From AG-120 to be Presented at EORTC-NCI-AACR 2014; AG-221 and AG-348 Data to be Presented at 2014 American Society of Hematology Annual Meeting

Company to Webcast R&D Day Today

Selecta Announces More than $20 Million in Equity Funding

Selecta Announces More than $20 Million in Equity Funding

October 15, 2014

WATERTOWN, Mass.–(BUSINESS WIRE)–Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced it has secured equity funding of more than $20 million from new and all of Selecta’s existing investors.